New Insights into the Underlying Biochemistry of Autism- The Mercury Connection PART 2 of 2 by Mark Geier, MD, PhD and David A Geier

This presentation will provide a clear and concise overview of new research examining the underlying biochemistry of autism. Attendees will understand how newly published research allows patients diagnosed with autism to be evaluated using clinically available, routine laboratory testing to identify specific biomarkers associated with medical dysfunction in autism. This will include examination of important biomarkers, including urinary porphyrins, transsulfuration metabolites, mitochondrial dysfunction, and hormonal disturbances. In addition, information will be presented on the latest large-scale population and clinical studies associated mercury intoxication with autism.

Mark R. Geier, MD, PhD
has an MD and a PhD in genetics. He is board certified in genetics by the American Board of Medical Genetics and is a Fellow of the American College of Epidemiology. Dr. Geier is a founder and medical director of ASD Centers, LLC (www.asdcenters.com), and has been in clinical practice for more than 29 years during which time he has been involved in the evaluation and treatment of more than 600 patients diagnosed with autism spectrum disorders. Dr. Geier was a researcher at the National Institutes of Health for 10 years. He was also a professor at the Johns Hopkins University and at the Uniformed Services University of the Health Sciences. Dr. Geier has published more than 100 peer-reviewed medical articles, including co-authoring more than 20 peer-reviewed studies on the relationship of genetic, biochemical and hormonal changes in autism, which has resulted in new insights as to the cause and treatment of autism. He has also helped to co-author a new book, "Sacred Spark" (www.sacredsparkbook.com) on autism. Dr. Geier has served as a scientific reviewer for autism grants for the U.S. Government. He has a patent pending for the treatment of patients diagnosed with autism. Dr. Geier has also been involved in vaccine/biologic litigation.

David A. Geier
is vice-president of the non-profit 501(c)3 Institute of Chronic Illnesses, Inc (www.iciautism.com) and the non-profit 501(c)3 CoMeD, Inc (www.mercury-freedrugs.org). David is also the executive director of ASD Centers, LLC (www.asdcenters.com). He graduated with honors from UMBC with a BA in Biology and a minor in History. He has been a researcher scientist at the National Institutes of Health. David has co-authored more than 50 peer-reviewed medical studies, and helped to co-author a new compelling new book, "Sacred Spark" (www.sacredsparkbook.com) on autism. Over the last few years David, as a member of the Institute of Chronic Illnesses, Inc. and CoMeD, Inc., has studied and co-authored more than 20 peer-reviewed studies on the relationship of genetic, biochemical and hormonal changes in autism, which has resulted in new insights as to the cause and treatment of autism. David has a patent pending for the treatment of patients diagnosed with autism. He has also been involved in vaccine/biologic litigation.